Analyst Price Targets — QDEL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 12, 2026 2:29 pm | — | UBS | $30.00 | $23.19 | TheFly | QuidelOrtho price target lowered to $30 from $35 at UBS |
| January 21, 2026 11:20 am | — | UBS | $35.00 | $32.73 | TheFly | QuidelOrtho price target raised to $35 from $31 at UBS |
| September 19, 2024 8:37 am | Lu Li | UBS | $50.00 | $46.23 | TheFly | QuidelOrtho assumed with Neutral from Sell at UBS |
| September 5, 2024 7:26 am | Bill Bonello | Craig-Hallum | $57.00 | $42.93 | StreetInsider | Craig-Hallum Upgrades Quidel Corp. (QDEL) to Buy |
| August 15, 2023 3:08 pm | Andrew Cooper | Raymond James | $110.00 | $74.47 | Benzinga | Analyst Is Frustrated By QuidelOrtho's Reduction In Guidance - Here's Why |
| December 12, 2022 7:28 am | — | Citigroup | $125.00 | $92.30 | Benzinga | Citigroup Upgrades QuidelOrtho to Buy, Raises Price Target to $125 |
| December 7, 2022 4:43 am | — | RBC Capital | $125.00 | $92.19 | Benzinga | RBC Capital Initiates Coverage On QuidelOrtho with Outperform Rating, Announces Price Target of $125 |
| October 14, 2022 8:11 am | Elizabeth Garcia | UBS | $86.00 | $76.38 | StreetInsider | UBS Upgrades Quidel Corp. (QDEL) to Neutral |
Latest News for QDEL
A board director at QuidelOrtho Corp. acquired 10,000 common shares on Feb. 13, 2026, at an average price of around $23.96 per share, totaling ~$240,000. All shares were acquired for direct ownership; indirect holdings via UGMA accounts and Birchview Fund, LLC, remain unchanged at 54,775 shares.
SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency…
SAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference. The Company's presentation is scheduled for Tuesday, March 3, 2026, at 1:40 p.m.
Public Sector Pension Investment Board lifted its stake in shares of QuidelOrtho Corporation (NASDAQ: QDEL) by 17.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 264,853 shares of the company's stock after buying an additional 38,935 shares during the quarter. Public
QuidelOrtho inks Lifotronic supply deal, adding 70+ assays and new analyzer platforms to boost global immunoassay reach and recurring revenue potential.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QDEL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.